Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Last trade$0.7515
Day change-$0.0215 (-2.78%)
Day range$0.739 – $0.804
Volume3,945,244
Market cap$262M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$261.27M
Price / earnings
—
Price / book
-14.78×
Price / sales
52.55×
EV / sales
64.67×
EV / EBITDA
-6.34×
Profitability
Earnings per share
-$0.14
Return on assets
-44.1%
Return on equity
269.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-4.8×
Current ratio
0.77×
Quick ratio
0.77×
Cash ratio
0.21×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$63.9M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OCGN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.95M
$1.49M
$1.53M
—
$1.75M
$1.37M
$1.48M
$764K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.95M
$1.49M
$1.53M
—
$1.75M
$1.37M
$1.48M
$764K
Selling, general and administrative
$7.2M
$7.24M
$8.12M
—
$8.23M
$6.77M
$6.45M
$6.31M
Research and development
$12.5M
$10.69M
$11.26M
—
$11.15M
$8.4M
$9.53M
$8.29M
Total operating expenses
$19.7M
$17.93M
$19.37M
—
$19.38M
$15.17M
$15.98M
$14.6M
Operating income
-$17.75M
-$16.44M
-$17.84M
—
-$17.63M
-$13.8M
-$14.5M
-$13.84M
Interest expense
-$3.09M
-$4.48M
-$1.32M
—
-$1.31M
-$1.29M
-$1.26M
-$601K
Income before taxes
-$3.6M
-$24.88M
-$19.18M
—
-$20.05M
-$14.74M
-$15.35M
-$13.88M
Income taxes
$0
$0
$0
—
$0
$0
$0
$0
Net income
-$3.6M
-$24.88M
-$19.18M
—
-$20.05M
-$14.74M
-$15.35M
-$13.88M
Net income attributable to common shareholders
-$3.6M
-$24.88M
-$19.18M
—
-$20.05M
-$14.74M
-$15.35M
-$13.88M
EBITDA
-$17.21M
-$15.86M
-$17.25M
-$397K
-$16.68M
-$12.55M
-$13.91M
-$13.24M
Basic earnings per share
-$0.01
-$0.07
-$0.06
—
-$0.07
-$0.05
-$0.05
-$0.05
Diluted earnings per share
-$0.01
-$0.07
-$0.06
—
-$0.07
-$0.05
-$0.05
-$0.05
Recent news
Company coverage with links to the original publishers.
Ocugen, Inc. announced it will present its innovative modifier gene therapy platform at three major conferences in September 2026, including the Citi Biopharma Back to School Conference, H.C. Wainwright Global Investment Conference, and The Retina Society Annual Scientific Meeting. The company will showcase 12-month Phase 2 results for OCU410 gene therapy for geographic atrophy.
Ocugen, Inc. announced it will present its innovative modifier gene therapy platform at multiple upcoming conferences in July 2026, including presentations at Piper Sandler Virtual Ophthalmology Day, OIS Retina Innovation Summit, and ASRS annual meeting. The company will showcase Phase 2 OCU410 results and clinical data for inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy.
A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.
The longevity biotech market is expanding rapidly, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034. Multiple companies are advancing cell and gene therapies targeting age-related diseases: Lineage Cell Therapeutics is developing islet therapy for Type 1 diabetes, Ocugen reported 46% lesion reduction in age-related macular degeneration, Vertex is advancing stem cell-derived islet therapy toward regulatory submissions, and Longeveron published positive Phase 2b data for age-related frailty treatment.
Ocugen announced a webcast on January 15, 2026 to discuss Phase 2 clinical trial data from the OCU410 ArMaDa trial, featuring leading ophthalmologists and company executives. The presentation will cover one-year follow-up data from the first half of patients treated with the modifier gene therapy for blindness diseases.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.